Term ends no later than Apr 19, 2034 · Medium confidence
20-year base term ends Aug 30, 2032
In force on USPTO's status record and by its fee record. A terminal disclaimer on file may shorten this term, possibly to a date already past; its reference document is unresolved, so the date above is an upper bound and no earlier date is guessed.
Held by Amgen Inc.
Filed Jan 26, 2015 as application 14/605,287 · Granted Jun 19, 2018
Base term plus 597 days of patent term adjustment (USPTO delay)
Today
2012
2034
Clock starts
Aug 30, 2012
Aug 30, 2012
Ends no later than
Apr 19, 2034
Apr 19, 2034
Granted
Jun 19, 2018
Jun 19, 2018
base term
patent term adjustment
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
597
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
16
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 597 days past its 20-year base term on prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. 2 of 3 maintenance fees are paid so far. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Aug 30, 2012, when application 13/600,114, the earliest non-provisional in its chain, was filed (this one was filed Jan 26, 2015) | Aug 30, 2032 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +597 days, USPTO patent term adjustment record | Apr 19, 2034 | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | no later than Apr 19, 2034 | Medium confidence |
This family
| US 8,939,935 | In force Aug 2032 | Aug 2032 |
| US 9,511,189 | In force Jan 2033 | Jan 2033 |
| US 9,707,337 | In force Jun 2033 | Jun 2033 |
| US D745,142 | In force Dec 2029 | Dec 2029 |
| US 9,814,832 | In force Jan 2034 | Jan 2034 |
| Application PCT/US2014/013005 | PCT application no patent term | no patent term |
| US 9,707,335 | In force Mar 2034 | Mar 2034 |
| US 9,999,727 | this patent no later than Apr 2034 | no later than Apr 2034 |
8 of 16 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Aug 10, 2017 Reel 43513, frame 959 | Unilife Corporation; Unilife Medical Solutions, Inc.; Unitract Syringe Pty Ltd. Acn 101 059 723; Unilife Medical Solutions Pty Limited Acn 008 071 403 | Unl Holdings LLC | Assignment of Assignor's Interest |
| Sep 11, 2017 Reel 43546, frame 573 | O'connor, Sean M.; Bokelman, Kevin; Hanson, Ian B.; Bente, Paul F., IV | Unitract Syringe Pty Ltd. | Assignment of Assignor's Interest |
| Oct 4, 2017 Reel 44117, frame 961 | Unilife Corporation; Unilife Medical Solutions, Inc.; Unitract Syringe Pty Ltd. Acn 101 059 723; Unilife Medical Solutions Pty Limited Acn 008 071 403 | Unl Holdings LLC | Assignment of Assignor's Interest |
| Oct 11, 2017 Reel 44172, frame 823 | Unilife Corporation; Unilife Medical Solutions, Inc.; Unitract Syringe Pty Ltd. Acn 101 059 723; Unilife Medical Solutions Pty Limited Acn 008 071 403 | Unl Holdings LLC | Corrective Assignment to Correct the Execution Date and Incorrect Appl. No. 29/606,628/ and Appl. No. 29/551,569 Previously Recorded at Reel: 043513 Frame: 0959. Assignor(S) Hereby Confirms the Assignment. |
| Oct 9, 2025 Reel 73057, frame 641 | Unl Holdings LLC | Amgen Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Apr 2034
Term ends no later than Apr 19, 2034. Maintenance fees still fall due before then
Note
A terminal disclaimer is on file and its reference is not resolved. No cap is applied and none is guessed
Note
The 597 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Open question
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Apr 19, 2034. We will not guess the cap.
Citations
13
later US patents cite this one
That is top 25% of utility patents granted in 2018 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
This computed term ends no later than the date shown; an unresolved terminal disclaimer may end it earlier. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.